Status:
COMPLETED
Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension
Lead Sponsor:
Allergan
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
20+ years
Phase:
PHASE2
Brief Summary
This study evaluates the safety and efficacy of once-daily bimatoprost 0.03% and 0.01% ophthalmic solutions compared with once-daily administered bimatoprost vehicle ophthalmic solution for 2 weeks in...
Eligibility Criteria
Inclusion
- Ethnically Japanese patients with glaucoma or ocular hypertension in each eye who require IOP-lowering therapy in both eyes
Exclusion
- Uncontrolled systemic disease
- Use of bimatoprost or an ocular prostaglandin (eg, latanoprost, travoprost) within 6 weeks prior to baseline (Day 0)
Key Trial Info
Start Date :
November 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2004
Estimated Enrollment :
111 Patients enrolled
Trial Details
Trial ID
NCT00651859
Start Date
November 1 2002
End Date
January 1 2004
Last Update
April 3 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
San Francisco, California, United States